Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

CALR mutation burden in essential thrombocythemia and disease outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Michaël Harnois, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Elena Nacca, Alessandro Atanasio, Ilaria Sestini, Audrey Désilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Lambert Busque, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2024) 143 (13): 1310–1314.

https://doi.org/10.1182/blood.2023023428

Published: 2024

Includes: Supplemental data

Journal Articles

Prospective Symptom Burden Analysis in 784 Patients with Myeloproliferative Neoplasms: High Burden Correlates with Inflammatory/Genetic Biomarkers and Reduced Survival

Alisa Poullet, Lambert Busque, Shireen Sirhan, Robert Delage, Ghislain Cournoyer, Ines Chamakhi, Danielle Talbot, Luigina Mollica, Daniele Marceau, Vincent Ethier, Pierre Desjardins, Harold J. Olney, Michaël Harnois, Natasha Szuber

Blood (2023) 142 (Supplement 1): 917.

https://doi.org/10.1182/blood-2023-183005

Published: 2023

Journal Articles

Perioperative Outcomes and Management in Patients with Myeloproliferative Neoplasms: A Multicentric Retrospective Analysis of 354 Surgical Interventions

Natasha Szuber, Steve Dagenais-Bellefeuille, Mégane Tanguay, Awatef Shehabeldeen, Saima Ahmed, Michaël Harnois, Jaroslav F. Prchal, Harold J. Olney, Lambert Busque, Shireen Sirhan

Blood (2023) 142 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2023-188259

Published: 2023

Journal Articles

Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Lambert Busque, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Alessandro Atanasio, Ilaria Sestini, Audrey Desilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Marie-Christine Meunier, Michael Harnois, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2023) 142 (Supplement 1): 6328.

https://doi.org/10.1182/blood-2023-174076

Published: 2023

Journal Articles

Prognostic Impact of High Calreticulin Variant Allele Frequency in Patients with Myeloproliferative Neoplasms

Audrey Desilets, Michael Harnois, Lambert Busque, Natasha Szuber

Blood (2022) 140 (Supplement 1): 9700–9701.

https://doi.org/10.1182/blood-2022-163785

Published: 2022

Journal Articles

Higher Rates of Perioperative Thrombosis and Distinct Management Practices in Secondary Erythrocytosis Versus Polycythemia Vera

Natasha Szuber, Michael Harnois, Robert Delage, Shireen Sirhan, Lambert Busque

Blood (2022) 140 (Supplement 1): 5661–5663.

https://doi.org/10.1182/blood-2022-170026

Published: 2022

Journal Articles

Real-Life Use of Nilotinib for Chronic Phase CML Demonstrates Similar Efficacy and Rate of Cardiovascular Events As Enestnd

Olivier Del Corpo, Michael Harnois, Lambert Busque, Sarit Assouline

Blood (2021) 138 (Supplement 1): 4602.

https://doi.org/10.1182/blood-2021-151761

Published: 2021

Journal Articles

Very Elderly Patients with Myeloproliferative Neoplasms: Phenotypic Distinctions and Prognostic Determinants of Complications and Mortality

Judith Jolin, Michael Harnois, Luigina Mollica, Pierre Laneuville, Robert Delage, Harold J. Olney, Shireen Sirhan, Lambert Busque, Natasha Szuber

Blood (2021) 138 (Supplement 1): 2572.

https://doi.org/10.1182/blood-2021-145131

Published: 2021

Journal Articles

Patterns of Care and Outcomes in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Multicenter Population-Based Study

Natasha Szuber, Judith Jolin, Michael Harnois

Blood (2021) 138 (Supplement 1): 3650.

https://doi.org/10.1182/blood-2021-148922

Published: 2021

Journal Articles

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Eliane Nguyen, MD, Natasha Szuber, MD, Michael Harnois, Lambert Busque, MD, Luigina Mollica, MD FRCPC, PhD, Sarit E Assouline, MD MSc, Ines Chamakhi, MD MD FRCP(C), Harold J. Olney, MD, Shireen Sirhan, MD

Blood (2020) 136 (Supplement 1): 4–7.

https://doi.org/10.1182/blood-2020-141835

Published: 2020

Journal Articles

Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study

Adi J. Klil-Drori, MD, Hui Yin, MSc, Laurent Azoulay, PhD, Alexa Del Corpo, Michael Harnois, Michel-Olivier Gratton, Lambert Busque, MD, Sarit Assouline, MD

Blood (2017) 130 (Supplement 1): 315.

https://doi.org/10.1182/blood.V130.Suppl_1.315.315

Published: 2017

Journal Articles

Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia

Adi J. Klil-Drori, MD, Laurent Azoulay, PhD, Hui Yin, MSc, Alexa Del Corpo, Michaël Harnois, MSc, Michel-Olivier Gratton, MSc, Ines Chamakhi, MD, Robert Delage, MD MSc, FRCP, Luigina Mollica, MD PhD, Pierre Laneuville, MD FRCPC, Harold J. Olney, MD CM, Lambert Busque, MD, Sarit E. Assouline, MDMSc

Blood (2016) 128 (22): 3072.

https://doi.org/10.1182/blood.V128.22.3072.3072

Published: 2016

Journal Articles

Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia

Adi J Klil-Drori, MD, Laurent Azoulay, PhD, Hui Yin, MSc, Michel-Olivier Gratton, MSc, Michaël Harnois, MSc, Ines Chamakhi, MD, Robert Delage, MD MSc, FRCP, Pierre Laneuville, MD FRCPC, Luigina Mollica, MD FRCPC, PhD, Harold J. Olney, MD CM, Lambert Busque, MD, Sarit E. Assouline, MDMSc

Blood (2015) 126 (23): 2778.

https://doi.org/10.1182/blood.V126.23.2778.2778

Published: 2015

NARROW

CALR mutation burden in essential thrombocythemia and disease outcome

Prospective Symptom Burden Analysis in 784 Patients with Myeloproliferative Neoplasms: High Burden Correlates with Inflammatory/Genetic Biomarkers and Reduced Survival

Perioperative Outcomes and Management in Patients with Myeloproliferative Neoplasms: A Multicentric Retrospective Analysis of 354 Surgical Interventions

Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome

Prognostic Impact of High Calreticulin Variant Allele Frequency in Patients with Myeloproliferative Neoplasms

Higher Rates of Perioperative Thrombosis and Distinct Management Practices in Secondary Erythrocytosis Versus Polycythemia Vera

Real-Life Use of Nilotinib for Chronic Phase CML Demonstrates Similar Efficacy and Rate of Cardiovascular Events As Enestnd

Very Elderly Patients with Myeloproliferative Neoplasms: Phenotypic Distinctions and Prognostic Determinants of Complications and Mortality

Patterns of Care and Outcomes in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Multicenter Population-Based Study

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study

Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia

Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only